Drug Combination Details
| General Information of the Combination (ID: C52902) | |||||
|---|---|---|---|---|---|
| Name | Bufalin NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | ||
| MKN45 | CVCL_0434 | Gastric adenocarcinoma | Homo sapiens | |||
| BGC-823 | CVCL_3360 | Gastric cancer | Homo sapiens | |||
| Experimental
Result(s) |
Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells. Mol Med Rep. 2016 Aug;14(2):1817-22. | |||
